The agency published an overview of marketing authorizations made in 2016.
On Jan. 17, 2017, the European Medicines Agency (EMA) published an overview of the market authorizations and the safety monitoring recommendations the agency made in 2016. EMA recommended 81 drugs for market authorization in 2016, which included 27 new active substances.
Some notable highlights from the report include 16 orphan drug designations in 2016. These drugs treat patients with hematology disorders, cancer, hepatology disorders, immunological problems, and metabolism disorders. There were also accelerated assessments made for authorization of treatments for unmet needs including different forms of cancer and chronic hepatitis C infections.
Source: EMA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.